News | July 20, 2009

ATS Medical Announces First Use of the New ATS CryoMaze 10-S Probe for Ablation


July 20, 2009 - ATS Medical Inc. today announced the first commercial use of the new ATS CryoMaze 10-S Surgical Cryoablation Probe for the treatment of cardiac arrhythmias.

The cryoablation procedure was performed by Niv Ad, M.D., chief of cardiac surgery at the Inova Heart and Vascular Institute in Falls Church, Virginia. The ATS CryoMaze 10-S Probe is a linear cryoablation probe that is more rigid than the current ATS CryoMaze probes. The increased support throughout the length of the 10-S probe addresses the preference of some surgeons to have more probe leverage to achieve contact with targeted tissue that is difficult to reach, the company said. In addition, the increased stiffness of the ATS CryoMaze 10-S Probe will optimize the shape retention of the malleable probe, which is particularly useful in minimally invasive procedures.

The new cryoablation probe leverages the second generation, argon-based ATS CryoMaze System that quickly achieves the coldest probe temperatures available for cardiac arrhythmia surgery, the company said. The argon-based cryoablation system routinely reaches probe temperatures of -160 degrees Celsius compared to first generation nitrous-oxide systems, which only reach temperatures of -65 degrees Celsius. The colder probe temperatures provide faster, deeper lesions yielding greater confidence that transmural, linear lesions are being achieved, especially in clinical situations in which varying tissue thickness is the rule, the company said.

The proprietary design utilized in all ATS CryoMaze Probes allows them to be easily shaped by hand without the need for a tool to control the radius of the bends. The probe tip can be repeatedly reshaped intraoperatively to meet the different anatomic requirements of the individual patient and procedure. The "bellows" design of the ATS CryoMaze Probes facilitates this durable probe malleability without kinking and/or fractures.

"The ATS CryoMaze System is very well equipped for minimally invasive stand-alone surgery for atrial fibrillation. The new, more rigid 10-S probe is a great addition that makes it easier to apply lesions and complete full biatrial Maze-III procedures," said Dr. Ad.

For more information: www.atsmedical.com

Related Content

News | Ablation Systems

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
News | Ablation Systems

May 4, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias ...

Home May 04, 2022
Home
News | Ablation Systems

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

Home April 05, 2021
Home
News | Ablation Systems

June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat ...

Home June 16, 2020
Home
News | Ablation Systems

May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SERF) ...

Home May 08, 2020
Home
Feature | Ablation Systems

May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or ...

Home May 08, 2020
Home
Videos | Ablation Systems

Clifford Robinson, M.D., associate professor of radiation oncology, chief of the SBRT service, director of clinical ...

Home September 26, 2019
Home
News | Ablation Systems

September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically ...

Home September 17, 2019
Home
News | Ablation Systems

May 16, 2019 — Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter ...

Home May 16, 2019
Home
News | Ablation Systems

May 16, 2019 — CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the ...

Home May 16, 2019
Home
Subscribe Now